In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog (PTEN)

Claudia Soto, Huang Chi Du, Robert Fox, Taegyun Yang, James Hooson, Noelle Anastasio, Scott R. Gilbertson, Kathryn A. Cunningham, Kathryn Cunningham, Scott R. Gilbertson

Research output: Contribution to journalArticle

Abstract

Hypofunction of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in a variety of disorders including substance use disorders. As such, approaches to enhance 5-HT2CR signaling display therapeutic potential. In the present study, we show that disruption of the 5-HT2CR interaction with the protein phosphatase and tensin homolog (PTEN) via peptidomimetic-based protein-protein interaction disrupters enhances 5-HT2CR-mediating signaling in vitro and potentiates selective 5-HT2CR agonists in behavioral rodent models. Overall, the present study provides further evidence that 5-HT2CR activity can be modulated through an allosteric protein-protein interaction. This work provides the groundwork for the continued exploration of protein-protein interactions that can allosterically modulate this critical receptor and other important GPCRs for new therapeutic development through mechanisms that may display clinical utility.

Original languageEnglish (US)
Article number907
JournalFrontiers in Pharmacology
Volume10
Issue numberJULY
DOIs
StatePublished - Jan 1 2019

Fingerprint

Receptor, Serotonin, 5-HT2C
Peptidomimetics
Phosphoric Monoester Hydrolases
Proteins
Serotonin
Serotonin 5-HT2 Receptor Agonists
Phosphoprotein Phosphatases
Substance-Related Disorders
In Vitro Techniques
Tensins
Rodentia
Therapeutics

Keywords

  • Drug discrimination
  • Peptidomimetics
  • Protein phosphatase and tensin homolog
  • Protein-protein interactions
  • Serotonin 2C receptor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog (PTEN). / Soto, Claudia; Du, Huang Chi; Fox, Robert; Yang, Taegyun; Hooson, James; Anastasio, Noelle; Gilbertson, Scott R.; Cunningham, Kathryn A.; Cunningham, Kathryn; Gilbertson, Scott R.

In: Frontiers in Pharmacology, Vol. 10, No. JULY, 907, 01.01.2019.

Research output: Contribution to journalArticle

Soto, Claudia ; Du, Huang Chi ; Fox, Robert ; Yang, Taegyun ; Hooson, James ; Anastasio, Noelle ; Gilbertson, Scott R. ; Cunningham, Kathryn A. ; Cunningham, Kathryn ; Gilbertson, Scott R. / In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog (PTEN). In: Frontiers in Pharmacology. 2019 ; Vol. 10, No. JULY.
@article{2b0f2308726b48bc96126c6f33a45e83,
title = "In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog (PTEN)",
abstract = "Hypofunction of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in a variety of disorders including substance use disorders. As such, approaches to enhance 5-HT2CR signaling display therapeutic potential. In the present study, we show that disruption of the 5-HT2CR interaction with the protein phosphatase and tensin homolog (PTEN) via peptidomimetic-based protein-protein interaction disrupters enhances 5-HT2CR-mediating signaling in vitro and potentiates selective 5-HT2CR agonists in behavioral rodent models. Overall, the present study provides further evidence that 5-HT2CR activity can be modulated through an allosteric protein-protein interaction. This work provides the groundwork for the continued exploration of protein-protein interactions that can allosterically modulate this critical receptor and other important GPCRs for new therapeutic development through mechanisms that may display clinical utility.",
keywords = "Drug discrimination, Peptidomimetics, Protein phosphatase and tensin homolog, Protein-protein interactions, Serotonin 2C receptor",
author = "Claudia Soto and Du, {Huang Chi} and Robert Fox and Taegyun Yang and James Hooson and Noelle Anastasio and Gilbertson, {Scott R.} and Cunningham, {Kathryn A.} and Kathryn Cunningham and Gilbertson, {Scott R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fphar.2019.00907",
language = "English (US)",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "JULY",

}

TY - JOUR

T1 - In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog (PTEN)

AU - Soto, Claudia

AU - Du, Huang Chi

AU - Fox, Robert

AU - Yang, Taegyun

AU - Hooson, James

AU - Anastasio, Noelle

AU - Gilbertson, Scott R.

AU - Cunningham, Kathryn A.

AU - Cunningham, Kathryn

AU - Gilbertson, Scott R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hypofunction of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in a variety of disorders including substance use disorders. As such, approaches to enhance 5-HT2CR signaling display therapeutic potential. In the present study, we show that disruption of the 5-HT2CR interaction with the protein phosphatase and tensin homolog (PTEN) via peptidomimetic-based protein-protein interaction disrupters enhances 5-HT2CR-mediating signaling in vitro and potentiates selective 5-HT2CR agonists in behavioral rodent models. Overall, the present study provides further evidence that 5-HT2CR activity can be modulated through an allosteric protein-protein interaction. This work provides the groundwork for the continued exploration of protein-protein interactions that can allosterically modulate this critical receptor and other important GPCRs for new therapeutic development through mechanisms that may display clinical utility.

AB - Hypofunction of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in a variety of disorders including substance use disorders. As such, approaches to enhance 5-HT2CR signaling display therapeutic potential. In the present study, we show that disruption of the 5-HT2CR interaction with the protein phosphatase and tensin homolog (PTEN) via peptidomimetic-based protein-protein interaction disrupters enhances 5-HT2CR-mediating signaling in vitro and potentiates selective 5-HT2CR agonists in behavioral rodent models. Overall, the present study provides further evidence that 5-HT2CR activity can be modulated through an allosteric protein-protein interaction. This work provides the groundwork for the continued exploration of protein-protein interactions that can allosterically modulate this critical receptor and other important GPCRs for new therapeutic development through mechanisms that may display clinical utility.

KW - Drug discrimination

KW - Peptidomimetics

KW - Protein phosphatase and tensin homolog

KW - Protein-protein interactions

KW - Serotonin 2C receptor

UR - http://www.scopus.com/inward/record.url?scp=85070718619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070718619&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00907

DO - 10.3389/fphar.2019.00907

M3 - Article

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JULY

M1 - 907

ER -